For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and the formulated version represents a true change. These novel therapies protect the transthyretin protein, halting its damaging build-up and reducing the impact of the condition . Patients are now seeing improvements i